company background image
PINK

Pilulka Lékárny SEP:PINK Stock Report

Last Price

Kč1.04k

Market Cap

Kč2.6b

7D

5.1%

1Y

-25.7%

Updated

17 Aug, 2022

Data

Company Financials
PINK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

PINK Stock Overview

Pilulka Lékárny a.s. operates a chain of pharmacies in the Czech Republic.

Pilulka Lékárny Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pilulka Lékárny
Historical stock prices
Current Share PriceKč1,040.00
52 Week HighKč1,800.00
52 Week LowKč930.00
Beta0
1 Month Change-1.89%
3 Month Change-12.61%
1 Year Change-25.71%
3 Year Changen/a
5 Year Changen/a
Change since IPO108.00%

Recent News & Updates

Shareholder Returns

PINKCZ Consumer RetailingCZ Market
7D5.1%0.3%-1.5%
1Y-25.7%-21.5%28.1%

Return vs Industry: PINK underperformed the CZ Consumer Retailing industry which returned -21% over the past year.

Return vs Market: PINK underperformed the CZ Market which returned 31.4% over the past year.

Price Volatility

Is PINK's price volatile compared to industry and market?
PINK volatility
PINK Average Weekly Movement9.8%
Consumer Retailing Industry Average Movement5.1%
Market Average Movement3.8%
10% most volatile stocks in CZ Market7.7%
10% least volatile stocks in CZ Market1.8%

Stable Share Price: PINK is more volatile than 90% of CZ stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: PINK's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CZ stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aPetr Kasahttps://www.pilulka.cz

Pilulka Lékárny a.s. operates a chain of pharmacies in the Czech Republic. It operates 140 pharmacies, as well as an e-shop. The company is headquartered in Prague, the Czech Republic.

Pilulka Lékárny Fundamentals Summary

How do Pilulka Lékárny's earnings and revenue compare to its market cap?
PINK fundamental statistics
Market CapKč2.60b
Earnings (TTM)Kč0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PINK income statement (TTM)
RevenueKč0
Cost of RevenueKč0
Gross ProfitKč0
Other ExpensesKč0
EarningsKč0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did PINK perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PINK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PINK?

Other financial metrics that can be useful for relative valuation.

PINK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does PINK's PB Ratio compare to its peers?

PINK PB Ratio vs Peers
The above table shows the PB ratio for PINK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.8x
4350 Medical System Network
1x10.3%JP¥12.9b
MDVL MedAvail Holdings
2.7x22.1%US$89.6m
GXH Green Cross Health
1.2xn/aNZ$197.7m
FAR Farmaè
2.2x73.3%€87.1m
PINK Pilulka Lékárny
n/an/aKč2.6b

Price-To-Book vs Peers: Insufficient data to calculate PINK's Price-To-Book Ratio vs. peers for valuation analysis.


Price to Earnings Ratio vs Industry

How does PINK's PE Ratio compare vs other companies in the European Consumer Retailing Industry?

Price-To-Book vs Industry: Insufficient data to calculate PINK's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is PINK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PINK PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PINK's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of PINK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PINK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PINK's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

  • Take a look at our analysis of PINK's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Future Growth

How is Pilulka Lékárny forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.8%

Forecasted Consumer Retailing industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pilulka Lékárny has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of PINK’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Pilulka Lékárny performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


7.5%

Historical Consumer Retailing annual earnings growth

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Pilulka Lékárny has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Discover strong past performing companies

  • When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Pilulka Lékárny's management and board experience and expertise to assess their ability to deliver on their strategic promises.

Financial Health

How is Pilulka Lékárny's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

In this section we usually analyse Pilulka Lékárny's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Pilulka Lékárny has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Discover healthy companies

  • Take a look at our analysis of PINK’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Pilulka Lékárny's financial data was last updated here.

Dividend

What is Pilulka Lékárny current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PINK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PINK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PINK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PINK's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PINK has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Petr Kasa

no data

Tenure

Mr. Petr Kasa serves as the Chief Executive Officer at Pilulka Lékárny a.s. (formerly known as Pilulka Lekarny). Mr. Kasa serves as the Chief Executive Officer since January 2018, Founding and Managing Par...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pilulka Lékárny a.s.'s employee growth, exchange listings and data sources


Key Information

  • Name: Pilulka Lékárny a.s.
  • Ticker: PINK
  • Exchange: SEP
  • Founded: NaN
  • Industry: Drug Retail
  • Sector: Consumer Retailing
  • Implied Market Cap: Kč2.600b
  • Shares outstanding: 2.50m
  • Website: https://www.pilulka.cz

Location

  • Pilulka Lékárny a.s.
  • Drahobejlova 1073/36
  • Praha 9
  • Prague
  • 190 00
  • Czech Republic

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/17 00:00
End of Day Share Price2022/08/17 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.